FOR IMMEDIATE RELEASE

CONTACT: John Lehmann
440.801.1540
jlehmann@imarcresearch.com

Jim Tabaczynski
440.835.4525
jptab@jptgrouppr.com

IMARC Expands Service Offerings

DSMB & CEC Provide Logical Extension to Clinical Monitoring

CLEVELAND, *Ohio* — IMARC Research, a contract research organization based in Strongsville, Ohio, announced that it has launched independent oversight capabilities by adding Data Safety Monitoring Boards (DSMBs) and Clinical Events Committees (CECs) to its existing monitoring, auditing, training, project management and consulting services.

IMARC President Sandra Maddock, who made the announcement, said, "Adding these independent DSMB and CEC oversight services is a natural progression of IMARC's existing medical monitoring services and is part of IMARC's 2015 strategic plan." She added that it also furthers IMARC's mission to protect human subjects involved in clinical research.

"We have been assembling these safety teams for nearly a year and are starting out with fully operational boards comprised of highly qualified physicians and statisticians in cardiovascular, peripheral vascular, women's health, renal, emergency medicine, cell therapy and other areas," Maddock continued. "These services will move IMARC into new therapeutic areas and help us continue to partner with our clients in ensuring human subject protection."

DSMB and CEC teams help ensure the safety and improve the credibility of clinical studies by adding an additional layer of independent safety review of trial data.

Data Safety Monitoring Boards (DSMB) review cumulative information from a study and provide safety oversight through recommendations to continue, terminate, or adjust a clinical study protocol. Clinical Events Committees (CEC) provide additional oversight by adjudicating individual adverse events within a study to determine if those events are related to the study product or procedure.

A privately-held, 16-year old company located in Strongsville, Ohio, IMARC Research, Inc. assists the clinical research community in the pursuit of FDA and worldwide approvals.

IMARC's effectiveness is built on its commitment to human subject protection and their dedication to ensuring study compliance in its partnership with clients. IMARC's approach – based solidly in both U.S. and international regulations – results in the support, proof and assurance researchers seek to overcome chaos caused by complexity, while achieving compliance through consistency. Providing committed, competent and confident consultation is how IMARC sets the highest standards for site outcomes and study partnerships. More information is available at: www.imarcresearch.com

– 30 –